| HOME >> BIOLOGY >> TECHNOLOGY |
LIALDA/MEZAVANT - Ulcerative colitis
Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIALDA had reached a market share of 8.0% (average annual market share 3.9%). LIALDA's product sales for the year to December 31, 2007 were $50.5 million. All initial launch stocks of LIALDA totaling $34.7 million were recognised into revenue during the year to December 31, 2007.
The product was launched in the UK in November 2007, Canada in January 2008 and further launches are planned in the EU during 2008, subject to the successful conclusion of pricing and reimbursement negotiations. In the UK and Ireland the product will be called MEZAVANT XL and Shire plans to market the product in most other EU countries as MEZAVANT.
Since the launch of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 24.9% as at December 31, 2007, up from 17.6% as at December 31, 2006.
FOSRENOL - Hyperphosphatemia
FOSRENOL is now available in 24 countries and global sales totaled $102.2 million for the year to December 31, 2007 (2006: $44.8 million). Outside the US, FOSRENOL has now been launched in Germany, France, UK, Italy and Spain (in January 2008) and a number of other countries. Sales of FOSRENOL outside the US for the year ended December 31, 2007 were $40.1 million (2006: $4.6 million).
US sales of FOSRENOL for the year to December 31, 2007 were up 54% to
$62.1 million compared to the same period in 2006 (2006: $40.2 million).
FOSRENOL's average market share of the US phosphate binder market increased
from 8.5% in 2006 to 8.6% in 2007. The increase in product sales is due to
a small wholesaler stocking increase in 2007 compared to significant
wholesaler de-stocking of initial launch stocks in 200
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |